External validation of cardiovascular risk scores in patients with Type 2 diabetes using the Spanish population-based CARDIANA cohort

Simple item page
dc.contributor.authorEnguita Germán, Mónica
dc.contributor.authorBallesteros-Domínguez, Asier
dc.contributor.authorTamayo Rodríguez, Ibai
dc.contributor.authorLibrero, Julián
dc.contributor.authorOscoz-Villanueva, Ignacio
dc.contributor.authorForga, Lluís
dc.contributor.authorGoñi-Iriarte, María José
dc.contributor.authorLafita, Javier
dc.contributor.authorLecea, Óscar
dc.contributor.authorParraza, Naiara
dc.contributor.authorIbáñez Beroiz, Berta
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.date.accessioned2025-07-30T18:37:12Z
dc.date.available2025-07-30T18:37:12Z
dc.date.issued2025-05-29
dc.date.updated2025-07-30T17:58:13Z
dc.description.abstractAims. There is an overabundance of cardiovascular disease (CVD) risk-prediction models applicable to patients with Type 2 diabetes (T2D), but most of them still require external validation. Our aim was to assess the performance of 18 CVD risk scores in a Spanish cohort of patients with T2D. Methods and results. The CARdiovascular Risk in patients with DIAbetes in Navarra (CARDIANA) cohort, which includes 20 793 individuals with T2D and no history of CVD, was used to externally validate 13 models developed in patients with T2D [Action in Diabetes and Vascular Disease (ADVANCE), Atherosclerosis Risk in Communities, Basque Country Prospective Complications and Mortality Study risk engine, Cardiovascular Healthy Study, Diabetes Cohort Study, DIAL2, DIAL2-extended, Fremantle, Kaasenbrood, Swedish National Diabetes Register (NDR), PREDICT1-diabetes, SCORE2-diabetes, and Wan] and 5 models developed in the general population (ASCVD, PREVENT-basic, PREVENT-full, QRISK2, and SCORE2). Harrell's C-statistic and calibration plots were used as measures of discrimination and calibration, respectively. There were 991 incident CVD events within 5 years of follow-up, resulting in a cumulative incidence of 5.0% (95% confidence interval 4.7-5.3). Discrimination ability was moderate for all the models, with SCORE2-diabetes, NDR, PREDICT1-diabetes, PREVENT-full, Wan, ADVANCE, and both DIAL2 models showing the highest C-index values. All models showed good calibration, although most of them required recalibration, with the exception of ADVANCE-, DIAL2-, and SCORE2-related models. Conclusion. In our context, models derived for or adapted to diabetes patients, as well as models derived in the general population but incorporating diabetes-related metabolic measures (such as Hb1Ac) as predictors, demonstrated better performance than the others. DIAL2, DIAL2-extended, SCORE2-diabetes, and ADVANCE showed optimal calibration even without recalibration, which implies greater applicability, especially for SCORE2-diabetes and ADVANCE because of their simplicity. Lay summary. There are many tools to predict cardiovascular risk for patients with Type 2 diabetes (T2D), but most of them need to be validated in other contexts. This study evaluates the performance of 18 risk-prediction tools in a Spanish cohort of patients with T2D (CARDIANA). Five models (DIAL2, DIAL2-extended, SCORE2-diabetes, PREDICT1-diabetes, and Action in Diabetes and Vascular Disease (ADVANCE)], specially designed for people with diabetes, together with the PREVENT-full model, designed for the general population but including diabetes-related metabolic control measures, such as Hb1Ac as a predictor, demonstrated the best accuracy in predicting cardiovascular risk for Spanish patients with T2D, with the DIAL2-extended model performing best, closely followed by the SCORE2-diabetes and ADVANCE models, which are easier to use in clinical settings for their simplicity.This research provides valuable and updated information on CVD risk-prediction models for patients with T2D. These results may help clinicians to choose the most suitable risk-prediction tool for their specific clinical setting and patient population and may help healthcare providers make better decisions regarding preventive interventions and patient care, improving healthcare quality and efficiency.en
dc.description.sponsorshipThis research was funded by the Instituto de Salud Carlos III, via grant PI15/02196, and via CONCEPT project (grants PI19/00154 and PI19/00381). It has also received Funding from the Research Network on Health Services in Chronic Diseases-REDISSEC grant RD16/0001/0014 and Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS) RD21/0016/0016, both Spanish Networks supported by Instituto de Salud Carlos III, and the European Regional Development Funding (ERDF).
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/zip
dc.identifier.citationEnguita-Germán, M., Ballesteros-Domínguez, A., Tamayo, I., Librero, J., Oscoz-Villanueva, I., Forga, L., Goñi-Iriarte, M. J., Lafita, J., Lecea, O., Parraza, N., Ibáñez-Beroiz, B. (2025) External validation of cardiovascular risk scores in patients with Type 2 diabetes using the Spanish population-based CARDIANA cohort. European Journal of Preventive Cardiology, 1-10. https://doi.org/10.1093/eurjpc/zwaf304.
dc.identifier.doi10.1093/eurjpc/zwaf304
dc.identifier.issn2047-4873
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/54529
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofEuropean Journal of Preventive Cardiology (2025), zwaf304, 1-10
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI15%2F02196/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00154/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00381/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0001%2F0014/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII//RD21%2F0016%2F0016/
dc.relation.publisherversionhttps://doi.org/10.1093/eurjpc/zwaf304
dc.rights© The Author(s) 2025. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License.
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCardiovascular diseaseen
dc.subjectType 2 diabetesen
dc.subjectRisk predictionen
dc.subjectExternal validationen
dc.subjectPopulation-based cohorten
dc.titleExternal validation of cardiovascular risk scores in patients with Type 2 diabetes using the Spanish population-based CARDIANA cohorten
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublicationea88491f-9642-4b5b-b1d7-02987d63fc1b
relation.isAuthorOfPublication488f1d4a-17fc-4f8c-87c0-8939257c87d7
relation.isAuthorOfPublication6cc547dc-8ec5-4b66-b920-358328d1f12c
relation.isAuthorOfPublication.latestForDiscoveryea88491f-9642-4b5b-b1d7-02987d63fc1b

Files

Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Enguita_ExternalValidation.pdf
Size:
883.37 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Enguita_ExternalValidation_MatCompl.zip
Size:
591.09 KB
Format:
ZIP
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak